Filing Flows › Health Care › Scribe Therapeutics (SCTX)
Scribe Therapeutics (SCTX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Sep 2, 2026 · Scribe Therapeutics (SCTX) Q2 2026 earnings results →
Q2 2026 Revenue down 61% year over year to $1.9M · 338¢ of every $1 of revenue lost · operating margin -489.8%
Scribe Therapeutics made $1.9M in Q2 2026 (-61% Y/Y). Operating margin -489.8%, net loss $6.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Sep 2, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.9M in Q2 2026, down 61% year over year.
Operating costs exceeded revenue by $9.4M, an operating margin of -489.8%. Total costs fell 32% while revenue fell 61%. The quarter ended with a net loss of $6.5M. Non-operating items added $3.1M, -50% of pre-tax earnings, so the bottom line overstates operating performance.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Sep 2, 2026 | $1.9M | -61% | -489.8% | −$6.5M | — |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Scribe Therapeutics
Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design™ approach and nature’s blueprint for improved cardiovascular health, Scribe’s initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes.
In its own words, from its 8-K, filed Sep 2, 2026.
Scribe Therapeutics against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -61% against the peers' median +11%. Operating margin: -489.8% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SCTX Scribe Therapeutics | Q2 2026 | $1.9M | -61% | -489.8% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Scribe Therapeutics 10-Q on SEC EDGAR · CIK 1853921 · Biological Products, (No Diagnostic Substances)
More on SCTX
History
Every quarter: Q2 2026 results